Serum neurofilament light as a biomarker in progressive multiple sclerosis

There is an unmet need in multiple sclerosis (MS) therapy for treatments to stop progressive disability. The development of treatments may be accelerated if novel biomarkers are developed to overcome the limitations of traditional imaging outcomes revealed in early phase trials. In January 2019, the...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neurology
Auteurs principaux: Kapoor, Raju, Smith, Kathryn E., Allegretta, Mark, Arnold, Douglas L., Carroll, William, Comabella, Manuel, Furlan, Roberto, Harp, Christopher, Kuhle, Jens, Leppert, David, Plavina, Tatiana, Sellebjerg, Finn, Sincock, Caroline, Teunissen, Charlotte E., Topalli, Ilir, von Raison, Florian, Walker, Elizabeth, Fox, Robert J.
Format: Artigo
Langue:Inglês
Publié: Lippincott Williams & Wilkins 2020
Sujets:
Views & Reviews
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7538221/
https://ncbi.nlm.nih.gov/pubmed/32675076
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000010346
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires